Literature DB >> 3150926

Lithium augmentation for treatment-resistant depression in the elderly.

J Lafferman1, K Solomon, P Ruskin.   

Abstract

Lithium has been used successfully to enhance the effectiveness of tricyclic and other antidepressants, monoamine oxidase inhibitors, and combinations of antipsychotics and antidepressants. The safety and efficacy of adding lithium to the treatment regimen was examined in 14 elderly patients with refractory depression. Seven of the 14 had a complete recovery, and three showed a partial response. Side effects, including peripheral weakness, severe fine tremor, and neurotoxicity, necessitated the discontinuation of lithium in three patients. In two other patients with side effects, lower dosages of lithium relieved their symptoms. Lithium augmentation appears to be a promising treatment for geriatric depressed patients who are unresponsive to or cannot tolerate other standard therapies.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3150926     DOI: 10.1177/089198878800100109

Source DB:  PubMed          Journal:  J Geriatr Psychiatry Neurol        ISSN: 0891-9887            Impact factor:   2.680


  4 in total

Review 1.  Differential pharmacokinetics of lithium in elderly patients.

Authors:  B A Sproule; B G Hardy; K I Shulman
Journal:  Drugs Aging       Date:  2000-03       Impact factor: 3.923

2.  What do patients in a lithium outpatient clinic know about lithium therapy?

Authors:  R T Schaub; A Berghoefer; B Müller-Oerlinghausen
Journal:  J Psychiatry Neurosci       Date:  2001-09       Impact factor: 6.186

Review 3.  Going beyond antidepressant monotherapy for incomplete response in nonpsychotic late-life depression: a critical review.

Authors:  Donovan T Maust; David W Oslin; Michael E Thase
Journal:  Am J Geriatr Psychiatry       Date:  2013-02-06       Impact factor: 4.105

Review 4.  Treatment-resistant Late-life Depression: Challenges and Perspectives.

Authors:  Christian Knöchel; Gilberto Alves; Benedikt Friedrichs; Barbara Schneider; Anna Schmidt-Rechau; Sofia Wenzler; Angelina Schneider; David Prvulovic; André F Carvalho; Viola Oertel-Knöchel
Journal:  Curr Neuropharmacol       Date:  2015       Impact factor: 7.363

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.